Tocagen (TOCA) PT Set at $25.00 by Chardan Capital

Chardan Capital set a $25.00 price objective on Tocagen (NASDAQ:TOCA) in a research report released on Tuesday, TipRanks reports. The firm currently has a buy rating on the stock.

Several other brokerages also recently issued reports on TOCA. Zacks Investment Research downgraded shares of Tocagen from a buy rating to a hold rating in a research report on Saturday, January 26th. ValuEngine downgraded shares of Tocagen from a buy rating to a hold rating in a research report on Monday. Leerink Swann initiated coverage on shares of Tocagen in a research report on Monday, April 15th. They set a market perform rating and a $10.26 price objective for the company. Cantor Fitzgerald initiated coverage on shares of Tocagen in a research report on Thursday, April 25th. They set an overweight rating and a $28.00 price objective for the company. Finally, HC Wainwright reissued a buy rating and set a $14.50 price objective on shares of Tocagen in a research report on Thursday, May 9th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock has an average rating of Buy and an average target price of $18.78.

Shares of NASDAQ TOCA opened at $8.93 on Tuesday. Tocagen has a fifty-two week low of $6.47 and a fifty-two week high of $15.80. The company has a market capitalization of $209.76 million, a P/E ratio of -3.66 and a beta of 3.29. The company has a current ratio of 5.05, a quick ratio of 5.05 and a debt-to-equity ratio of 0.75.



Tocagen (NASDAQ:TOCA) last issued its earnings results on Tuesday, May 7th. The company reported ($0.74) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.75) by $0.01. Tocagen had a negative net margin of 294.74% and a negative return on equity of 108.08%. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $2.01 million. Research analysts predict that Tocagen will post -3.05 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in TOCA. BNP Paribas Arbitrage SA grew its position in Tocagen by 72,350.0% in the first quarter. BNP Paribas Arbitrage SA now owns 4,347 shares of the company’s stock valued at $47,000 after purchasing an additional 4,341 shares in the last quarter. Meeder Asset Management Inc. lifted its stake in Tocagen by 162.8% in the fourth quarter. Meeder Asset Management Inc. now owns 9,961 shares of the company’s stock valued at $82,000 after acquiring an additional 6,170 shares during the last quarter. Stratos Wealth Partners LTD. lifted its stake in Tocagen by 9.0% in the fourth quarter. Stratos Wealth Partners LTD. now owns 11,449 shares of the company’s stock valued at $94,000 after acquiring an additional 949 shares during the last quarter. Caption Management LLC acquired a new stake in Tocagen in the fourth quarter valued at $98,000. Finally, Creative Planning acquired a new stake in Tocagen in the first quarter valued at $117,000. 36.58% of the stock is owned by institutional investors and hedge funds.

Tocagen Company Profile

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

See Also: What is a Tariff?

Analyst Recommendations for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.